September 2025 Full renewal of the Board of Directors – Election of Dr. Markus Cappel as Chairman of the Board of Directors
September 2025 OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
September 2025 Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital – Clarification in Response to Unfounded Accusations
September 2025 Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
September 2025 Update on Information Relating to the General Meeting of September 30, 2025 – 61 Founding, Historical, Employee and Executive Shareholders of the Company, Representing Approximately 20.1% of Voting Rights have entered into a Shareholders’ Agreement
September 2025 OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer